Dexmedetomidine alleviates doxorubicin cardiotoxicity by inhibiting mitochondrial reactive oxygen species generation
- 85 Downloads
Cardiotoxicity largely limits the application of doxorubicin (Dox) for cancer treatment. Dexmedetomidine (Dex), a selective agonist of α2-adrenergic receptor, has been suggested to exert cardioprotection against myocardial injury. However, the effect and underlying mechanisms of Dex on Dox cardiotoxicity remain unknown. In this study, C57BL/6 mice were treated with Dox followed by Dex administration. Cardiomyocytes were co-incubated with Dox and Dex in vitro. The results showed that Dex markedly attenuated cardiac dysfunction induced by Dox. TUNEL staining exhibited that Dex inhibited Dox-induced cardiomyocyte apoptosis in myocardium. Moreover, the expression of anti-apoptotic protein Bcl-2 was increased, whereas the expression of pro-apoptotic protein Bax was decreased by Dex. Dox-induced the increase of reactive oxygen species (ROS), superoxide anion, and mitochondrial ROS (mROS) generation in myocardial tissues were significantly inhibited after Dex administration. In in vitro study, it was further confirmed that Dex prevented Dox-induced cardiomyocyte apoptosis and injury. However, the stimulation of mROS generation reversed the effect of Dex in cardiomyocytes. Mechanically, Dex blocked Dox-induced the ubiquitination of peroxisome proliferator-activated receptor gamma coactivator 1-α (PGC-1α), leading to the restoration of PGC-1α and downstream oxidative stress-protective molecules uncoupling protein 2 and manganese-dependent superoxide dismutase expression. Taken together, this study demonstrates that Dex exerts cardioprotection against Dox cardiotoxicity by attenuating mitochondrial dysfunction, oxidative stress, and cardiomyocyte apoptosis via inhibiting PGC-1α-signaling pathway inactivation. This suggests that Dex may be a potential therapeutic strategy for Dox cardiotoxicity treatment.
KeywordsDexmedetomidine Doxorubicin Cardiotoxicity Cardiomyocyte apoptosis Oxidative stress PGC-1α
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All mice experiments were performed according to the guidelines by the Association for Assessment and Accreditation of Laboratory Animal Care International and approved by the Institutional Animal Ethics Committee of Tongji University.
- 1.Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA, Ewer MS. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31. https://doi.org/10.1161/01.CIR.0000133187.74800.B9.CrossRefPubMedGoogle Scholar
- 2.Khaliq NU, Sandra FC, Park DY, Lee JY, Oh KS, Kim D, Byun Y, Kim IS, Kwon IC, Kim SY, Yuk SH. Doxorubicin/heparin composite nanoparticles for caspase-activated prodrug chemotherapy. Biomaterials. 2016;101:131–42. https://doi.org/10.1016/j.biomaterials.2016.05.056.CrossRefPubMedGoogle Scholar
- 3.Kern P, Kalisch A, von Minckwitz G, Putter C, Kolberg HC, Pott D, Kurbacher C, Rezai M, Kimmig R. Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival. J Chemother. 2016;28(3):210–7. https://doi.org/10.1179/1973947815Y.0000000061.CrossRefPubMedGoogle Scholar
- 9.Huang J, Jiang Q. Dexmedetomidine protects against neurological dysfunction in a mouse intracerebral hemorrhage model by inhibiting mitochondrial dysfunction-derived oxidative stress. J Stroke Cerebrovasc Dis. 2019;28(5):1281–9. https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.01.016.CrossRefPubMedGoogle Scholar
- 11.Xie C, Li Y, Liang J, Xiao J, Zhao Z, Li T. The effect of dexmedetomidine on autophagy and apoptosis in intestinal ischemia reperfusion-induced lung injury. Chin J Tuberc Respir Dis. 2015;38(10):761–4.Google Scholar
- 16.Cheng X, Hu J, Wang Y, Ye H, Li X, Gao Q, Li Z. Effects of dexmedetomidine postconditioning on myocardial ischemia/reperfusion injury in diabetic rats: role of the PI3K/Akt-dependent signaling pathway. J Diabetes Res. 2018;2018:3071959. https://doi.org/10.1155/2018/3071959.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Cao Y, Ruan Y, Shen T, Huang X, Li M, Yu W, Zhu Y, Man Y, Wang S, Li J. Astragalus polysaccharide suppresses doxorubicin-induced cardiotoxicity by regulating the PI3k/Akt and p38MAPK pathways. Oxid Med Cell Longev. 2014;2014:674219. https://doi.org/10.1155/2014/674219.CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Liu XR, Li T, Cao L, Yu YY, Chen LL, Fan XH, Yang BB, Tan XQ. Dexmedetomidine attenuates H2O2-induced neonatal rat cardiomyocytes apoptosis through mitochondria- and ER-medicated oxidative stress pathways. Mol Med Rep. 2018;17(5):7258–64. https://doi.org/10.3892/mmr.2018.8751.CrossRefPubMedPubMedCentralGoogle Scholar
- 22.St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 2006;127(2):397–408. https://doi.org/10.1016/j.cell.2006.09.024.CrossRefPubMedGoogle Scholar
- 24.Kroller-Schon S, Jansen T, Schuler A, Oelze M, Wenzel P, Hausding M, Kerahrodi JG, Beisele M, Lackner KJ, Daiber A, Munzel T, Schulz E. Peroxisome proliferator-activated receptor gamma, coactivator 1alpha deletion induces angiotensin II-associated vascular dysfunction by increasing mitochondrial oxidative stress and vascular inflammation. Arterioscler Thromb Vasc Biol. 2013;33(8):1928–35. https://doi.org/10.1161/ATVBAHA.113.301717.CrossRefPubMedGoogle Scholar
- 25.Addabbo F, Montagnani M, Goligorsky MS. Mitochondria and reactive oxygen species. Hypertension. 2009;53(6):885–92. https://doi.org/10.1161/HYPERTENSIONAHA.109.130054.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Shoukry HS, Ammar HI, Rashed LA, Zikri MB, Shamaa AA, Abou Elfadl SG, Rub EA, Saravanan S, Dhingra S. Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity. PLoS One. 2017;12(7):e0181535. https://doi.org/10.1371/journal.pone.0181535.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Zhang JJ, Peng K, Zhang J, Meng XW, Ji FH. Dexmedetomidine preconditioning may attenuate myocardial ischemia/reperfusion injury by down-regulating the HMGB1-TLR4-MyD88-NF-small ka, CyrillicB signaling pathway. PloS One. 2017;12(2):e0172006. https://doi.org/10.1371/journal.pone.0172006.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Chen Y, Feng X, Hu X, Sha J, Li B, Zhang H, Fan H. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxid Med Cell Longev. 2018;2018:4035310. https://doi.org/10.1155/2018/4035310.CrossRefPubMedPubMedCentralGoogle Scholar